ASTELLAS PHARMA
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
- Conditions
- Geographic AtrophyAge-Related Macular Degeneration
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 20
- Registration Number
- NCT06970665
- Locations
- 🇯🇵
Kyoto University Hospital, Kyoto-shi, Kyoto, Japan
🇯🇵Nihon University Hospital, Chiyoda-ku, Tokyo, Japan
🇯🇵Mie University Hospital, Tsu-shi, Mie, Japan
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 175
- Registration Number
- NCT06364696
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 277
- Registration Number
- NCT06206421
- Locations
- 🇯🇵
Daido Clinic, Nagoya-shi, Aichi, Japan
🇯🇵Juno Vesta Clinic hatta, Matsudo-shi, Chiba, Japan
🇯🇵Mori Ladies Clinic, Fukuoka-shi, Fukuoka, Japan
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 390
- Registration Number
- NCT06206408
- Locations
- 🇯🇵
Chita Kosei Hospital, Chita-gun, Aichi, Japan
🇯🇵Konan Kosei Hospital, Konan-City, Aichi, Japan
🇯🇵Daido Clinic, Nagoya-shi, Aichi, Japan
A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery
- Conditions
- MelanomaSentinel Lymph Node BiopsyBreast Cancer
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1
- Registration Number
- NCT05457842
- Locations
- 🇺🇸
UCI Irvine Health-Chao Family Comprehensive Cancer Center Cancer, Orange, California, United States
A Study of ASP3082 in Adults With Advanced Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- Drug: Nanoparticle albumin-bound-paclitaxelDrug: Oxaplatin
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 651
- Registration Number
- NCT05382559
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸UCLA Santa Monica Hematology Oncology, Santa Monica, California, United States
🇺🇸Denver HealthONE Drug Development Unit, Denver, Colorado, United States
A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 147
- Registration Number
- NCT05034042
- Locations
- 🇯🇵
Juno Vesta Clinic Hatta, Matsudo-shi, Chiba, Japan
🇯🇵Mori Ladies Clinic, Fukuoka-shi, Fukuoka, Japan
🇯🇵SANO Women's Clinic, Fukuoka-shi, Fukuoka, Japan
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 12
- Registration Number
- NCT04878471
- Locations
- 🇯🇵
JP81001, Sumida-ku, Tokyo, Japan
A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 34
- Registration Number
- NCT04641962
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 2104
- Registration Number
- NCT04408820
- Locations
- 🇯🇵
Site JP00023, Aichi, Japan
🇯🇵Site JP00005, Akita, Japan
🇯🇵Site JP00002, Aomori, Japan